{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Skin+Head+and+Neck&page=2",
    "query": {
      "condition": "Malignant Neoplasm of Skin Head and Neck",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 186,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Skin+Head+and+Neck&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Skin+Head+and+Neck&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T23:49:40.323Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04491942",
      "title": "Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Bile Duct Carcinoma",
        "Advanced Breast Carcinoma",
        "Advanced Cervical Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Esophageal Carcinoma",
        "Advanced Gastric Carcinoma",
        "Advanced Head and Neck Carcinoma",
        "Advanced Lung Non-Small Cell Carcinoma",
        "Advanced Lung Small Cell Carcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Ovarian Carcinoma",
        "Advanced Penile Carcinoma",
        "Advanced Pleural Malignant Mesothelioma",
        "Advanced Urothelial Carcinoma",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Distal Bile Duct Cancer AJCC v8",
        "Stage III Intrahepatic Bile Duct Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Penile Cancer AJCC v8",
        "Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Distal Bile Duct Cancer AJCC v8",
        "Stage IV Intrahepatic Bile Duct Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Penile Cancer AJCC v8",
        "Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8",
        "Triple-Negative Breast Carcinoma",
        "Unresectable Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Elimusertib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2021-08-25",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-08T23:49:40.323Z",
      "location_count": 7,
      "location_summary": "Sacramento, California • Bethesda, Maryland • New York, New York + 3 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04491942"
    },
    {
      "nct_id": "NCT00667641",
      "title": "Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Prostate Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-03",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2011-05-10",
      "last_synced_at": "2026-10-08T23:49:40.323Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00667641"
    },
    {
      "nct_id": "NCT04007744",
      "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Locally Advanced Gastric Adenocarcinoma",
        "Locally Advanced Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Gastric Adenocarcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Urothelial Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Refractory Lung Non-Small Cell Carcinoma",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sonidegib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2020-02-13",
      "completion_date": "2027-07-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-10-08T23:49:40.323Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04007744"
    },
    {
      "nct_id": "NCT00797043",
      "title": "Photon/Proton Radiation Therapy for Carcinoma of the Skin of the Head and Neck",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Malignant Neoplasm of Skin Head and Neck"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2008-09",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2017-02-07",
      "last_synced_at": "2026-10-08T23:49:40.323Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00797043"
    },
    {
      "nct_id": "NCT00582647",
      "title": "Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Esophageal Cancer",
        "Bile Duct Neoplasms",
        "Gastric Cancer",
        "Liver Cancer",
        "Melanoma",
        "Pancreatic Cancer",
        "Sarcoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6000,
      "start_date": "2000-03",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-10-08T23:49:40.323Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00582647"
    },
    {
      "nct_id": "NCT05169437",
      "title": "Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Breast Tumor",
        "Colon Tumor, Malignant",
        "Lung Tumor",
        "Urologic Cancer",
        "Pancreatic Cancer",
        "Melanoma",
        "Metastatic Cancer",
        "Locally Advanced Solid Tumor",
        "Esophageal Cancer",
        "Endometrial Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tempus AI",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2022-03-15",
      "completion_date": "2024-08-27",
      "has_results": true,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-08T23:49:40.323Z",
      "location_count": 80,
      "location_summary": "Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more",
      "locations": [
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05169437"
    },
    {
      "nct_id": "NCT01552434",
      "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "Castleman Disease",
        "Digestive System Carcinoma",
        "Erdheim-Chester Disease",
        "Lip and Oral Cavity Carcinoma",
        "Lymphangioleiomyomatosis",
        "Malignant Endocrine Neoplasm",
        "Malignant Female Reproductive System Neoplasm",
        "Malignant Male Reproductive System Neoplasm",
        "Malignant Neoplasm",
        "Malignant Respiratory Tract Neoplasm",
        "Malignant Thoracic Neoplasm",
        "Malignant Urinary System Neoplasm",
        "Mesothelial Neoplasm",
        "Metastatic Malignant Neoplasm",
        "Metastatic Urothelial Carcinoma",
        "Neurofibromatosis Type 2",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Digestive System Carcinoma",
        "Recurrent Female Reproductive System Carcinoma",
        "Recurrent Male Reproductive System Carcinoma",
        "Recurrent Malignant Neoplasm",
        "Recurrent Pharyngeal Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Malignant Neoplasm",
        "Soft Tissue Neoplasm",
        "Stage III Breast Cancer AJCC v7",
        "Stage III Pharyngeal Cancer",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Pharyngeal Cancer",
        "Stage IVA Pharyngeal Cancer",
        "Stage IVB Pharyngeal Cancer",
        "Stage IVC Pharyngeal Cancer",
        "Thyroid Gland Neoplasm"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 154,
      "start_date": "2012-10-16",
      "completion_date": "2026-05-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-08T23:49:40.323Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01552434"
    },
    {
      "nct_id": "NCT07405086",
      "title": "Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Advanced Biliary Tract Carcinoma",
        "Advanced Head and Neck Squamous Cell Carcinoma",
        "Advanced Hepatocellular Carcinoma",
        "Advanced Lung Non-Small Cell Carcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Melanoma",
        "Advanced Renal Cell Carcinoma",
        "Metastatic Biliary Tract Carcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Renal Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Immune Checkpoint Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2026-06-08",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-08T23:49:40.323Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07405086"
    },
    {
      "nct_id": "NCT00073944",
      "title": "BCX-1777 in Treating Patients With Refractory Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "forodesine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioCryst Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-30",
      "last_synced_at": "2026-10-08T23:49:40.323Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00073944"
    },
    {
      "nct_id": "NCT04099277",
      "title": "A Study of LY3435151 in Participants With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Triple-negative Breast Cancer",
        "Gastric Adenocarcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Cervical Carcinoma",
        "High Grade Serous Ovarian Carcinoma",
        "Hepatocellular Carcinoma",
        "Undifferentiated Pleomorphic Sarcoma",
        "Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "LY3435151",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2019-10-28",
      "completion_date": "2020-03-05",
      "has_results": true,
      "last_update_posted_date": "2021-08-31",
      "last_synced_at": "2026-10-08T23:49:40.323Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04099277"
    }
  ]
}